Company intelligence / Profile preview
Accentia Biopharmaceuticals
Tampa, Florida, United Statesaccentia.net ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company had two lead products in Phase 3 clinical trials: SinuNase for chronic sinusitis and BiovaxID for follicular non-Hodgkin's lymphoma. Both products received Fast Track designation from the FDA. Additionally, their Revimmune product received Orphan Drug Status for prevention of GVHD following bone marrow transplantation.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Biologicsvaccinesanti-fungals
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Mayo Foundation for Medical Education and ResearchNational Cancer Institute
Beyond the preview
Go deeper on Accentia Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Accentia Biopharmaceuticals.